ABSTRACT
Dysbiosis has been linked to the pathogenesis of multiple diseases. Although dozens of publications have associated changes in the nasopharyngeal microbiota to patient’s susceptibility to COVID-19, results from these studies are highly variable and contradictory in many cases. Addressing the limitations in previous research responsible for that variability, this study uses 16S rRNA gene sequencing to analyse the nasopharyngeal microbiota of 395 subjects, 117 uninfected controls and 278 COVID-19 patients, of different age groups that cover the entire lifespan and across varying disease severities. Importantly, our results reveal that bacterial diversity decreases progressively throughout life but only in severely ill COVID-19 patients, in whose nasopharynx, moreover, the opportunistic pathogen bacterial genera Staphylococcus, Corynebacterium, Streptococcus, Prevotella, Acinetobacter, and Pseudomonas are overrepresented. Notably, Scardovia wiggsiae appears only in severe COVID-19 patients over 60 years of age, suggesting a potential utility of this bacterial species as a COVID-19 severity biomarker in the elderly, who are the most susceptible individuals to suffer from serious forms of the disease and the age group that presents more differences in comparison with the other age groups according to the majority of the parameters analysed in this study. Our results provide valuable insights into age-associated dynamics within nasopharyngeal microbiota during severe COVID-19, offering potential avenues for further exploration and therapeutic interventions.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the grant 00006/COVI/20 to VM and MLC funded by Fundación Séneca-Murcia, the Saavedra Fajardo contract 21118/SF/19 to SC funded by Fundación Séneca-Murcia, the Juan de la Cierva-Incorporación contract to SDT funded by Ministerio de Ciencia y Tecnología/AEI/FEDER. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All procedures in this work were carried out following the principles expressed in the Declaration of Helsinki, as well as in all the other applicable international, national, and/or institutional guidelines for the use of samples and data, and have been approved by the Comité de ética de la Investigación (CEIm) at Hospital Clínico Universitario Virgen de la Arrixaca (protocol number 2020-10-12-HCUVA-Effects of aging in the susceptibility to SARS-CoV-2).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Raw sequencing data of all 16S rRNA sequences and metadata are available at the open access repository Figshare under the accession numbers 10.6084/m9.figshare.24504259 and 10.6084/m9.figshare.24504262, respectively.
